Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic lymphocytic leukaemia16.01.06.001; 01.10.06.0010.000035%Not Available
Chronic myeloid leukaemia16.01.07.001; 01.10.07.0010.000035%Not Available
Circulatory collapse24.06.02.0010.000210%Not Available
Clonus17.02.05.0020.000035%Not Available
Coagulopathy01.01.02.0010.000122%Not Available
Cold sweat08.01.03.024; 23.02.03.0020.000070%Not Available
Colitis07.08.01.0010.000227%
Colitis ischaemic24.04.08.012; 07.08.01.0040.000140%Not Available
Colitis ulcerative10.02.01.004; 07.08.01.0050.000367%Not Available
Colon cancer16.13.01.001; 07.21.01.0010.000087%Not Available
Condition aggravated08.01.03.0040.002635%Not Available
Conjunctival oedema06.04.01.0010.000035%Not Available
Conjunctivitis06.04.01.002; 11.01.06.012--
Coordination abnormal17.02.02.0040.000070%Not Available
Corneal deposits06.06.03.0020.000140%Not Available
Corneal epithelium defect06.06.03.0120.000087%Not Available
Corneal lesion06.06.03.0040.000087%Not Available
Corneal opacity06.06.03.0050.000087%Not Available
Coronary artery thrombosis02.02.01.007; 24.01.05.0020.000035%Not Available
Costochondritis15.07.03.0010.000052%Not Available
Cranial nerve palsies multiple17.04.01.0030.000035%Not Available
Crohn's disease10.02.01.005; 07.08.01.0150.000472%Not Available
Cushing's syndrome05.01.01.001; 24.08.04.001; 19.07.03.002; 14.11.01.0070.000961%Not Available
Cushingoid24.08.02.004; 19.07.03.001; 14.11.01.006; 05.01.01.0020.000748%
Cyanosis02.11.04.004; 24.03.01.007; 22.02.02.007; 23.06.04.0050.000070%
Deafness neurosensory17.04.07.001; 04.02.01.0020.000087%Not Available
Decreased activity19.11.01.002; 08.01.01.0060.000087%Not Available
Decreased immune responsiveness10.02.01.0410.000035%Not Available
Delirium19.13.02.0010.000297%
Delusional disorder, unspecified type19.03.03.0020.000035%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene